A team of engineers and medical researchers found that the technology enabled...
A team of engineers and medical researchers found that the technology enabled surgeons to pick up clinically relevant cancers that were missed when using current visual detection methods.
Source: University College London
13.12.2018 •

Technology pinpoints biopsies to detect prostate cancer

A team of engineers and medical researchers found that the technology enabled surgeons to pick up clinically relevant cancers that were missed when using current visual detection methods. The best approach would be to use both techniques in tandem, according to the findings published in European Urology. The software is deployed via a system called SmartTarget.

The advent of MRI-targeted biopsies, where MRI scans are used to inform surgeons where a tumour lies before they conduct a biopsy (tissue sample), has improved detection rates to close to 90% from 50% in the last five years. Now, the SmartTarget system has further enhanced this technique by allowing a 3D model of the prostate and cancer to be created for each patient from their MRI scans using advanced image processing and machine learning algorithms.

During a biopsy, this model is fused with ultrasound images to highlight the area of concern, which otherwise does not appear in the ultrasound images, helping to guide the surgeon while conducting the procedure.

Until last year when MRI targeting was introduced, the established way to test for prostate cancer involved taking a biopsy from the prostate without knowing where in the prostate a tumour was likely to be, resulting in close to half of life-threatening cancers being missed. “Prostate cancer detection has been improving at a very fast rate in recent years, and this technology pushes the science forward even further, enabling clinicians to pick up prostate cancer quickly so that patients can access the right treatment early enough,” said co-senior author Professor Hashim Ahmed, who began the research in UCL Medicine before moving to Imperial College London.

For the present study, 129 people with suspected prostate cancer underwent two biopsies—one using the SmartTarget system, and one where surgeons could only visually review the MRI scans. The two strategies combined detected 93 clinically significant prostate cancers, with each of them picking up 80 of these cancers; each missed 13 that the other method picked up.

The researchers say that surgeons’ visual review of MRI scans should be used in tandem with SmartTarget as using this technique enables surgeons to learn to make subtle adjustments such as adapting to the movement of the patient and the prostate as the needle is inserted. “We developed the SmartTarget system to equip surgeons with vital information about the size, shape and location of prostate tumours during a biopsy that is otherwise invisible on ultrasound images,” explained co-senior author Dr. Dean Barratt (UCL Medical Physics & Biomedical Engineering and UCL Centre for Medical Image Computing), who invented and led the development of the SmartTarget system. “The software provides them with a clear target. As MRI-targeted biopsies require a very high degree of expertise and experience, we hope that the imagery displayed by SmartTarget will help to bring high accuracy prostate cancer diagnosis to a much wider range of patients and hospitals.”

The researchers say the new methods could reduce the number of biopsies needed, and reduce the unnecessary surgeries caused by over diagnosis of less harmful cancers.

The inter-disciplinary study brought together engineers, urologists and radiologists, supported by the UCL Translational Research Office in project management and navigating the translational and regulatory pathway involved in taking the project from the lab bench to the operating room. “There has been much discussion and speculation in the media recently on the degree to which computers and artificial intelligence will be integrated into clinical care. Studies such as this one are extremely important as they provide valuable evidence on the performance of a new technology in the clinical setting,” said co-senior author Professor Mark Emberton (Dean, UCL Medical Sciences). “With this study we now have hard data showing that SmartTarget is as good as a group of experts in targeting tumours in the prostate, and have a glimpse of how clinicians and computers will be working together in the future for the good of the patient.”

Subscribe to our newsletter

Related articles

Using AI to predict risk of thyroid cancer on ultrasound

Using AI to predict risk of thyroid cancer on ultrasound

Researchers from Thomas Jefferson University use machine learning on ultrasound images of thyroid nodules to predict risk of malignancy.

MURAB: Roboter-assisted diagnostic of breast cancer

MURAB: Roboter-assisted diagnostic of breast cancer

The Murab project is developing technology that will make it possible to take more accurate biopsies and diagnose cancer and other illnesses faster.

Machine learning enhances brain tumour diagnosis

Machine learning enhances brain tumour diagnosis

A new AI approach classifies a common type of brain tumour into low or high grades with almost 98% accuracy, researchers report.

Hybrid microscope could bring digital biopsy to the clinic

Hybrid microscope could bring digital biopsy to the clinic

By adding infrared capability to the ubiquitous, standard optical microscope, researchers hope to bring cancer diagnosis into the digital era.

AI & MRI look into the genome of brain tumors

AI & MRI look into the genome of brain tumors

Researcher have developed a computer method that uses MRI and machine learning to rapidly forecast genetic mutations in glioma tumors,

Using AI to detect and grade prostate cancer

Using AI to detect and grade prostate cancer

Researchers have developed a method based on artificial intelligence for histopathological diagnosis and grading of prostate cancer.

Sensor chip detects cancer biomarker in urine

Sensor chip detects cancer biomarker in urine

Researchers have used a chip-based sensor with an integrated laser to detect very low levels of a cancer protein biomarker in a urine sample.

Deep learning identifies molecular patterns of cancer

Deep learning identifies molecular patterns of cancer

An AI platform can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process.

AI system predicts which cancer patients benefit from immunotherapy

AI system predicts which cancer patients benefit from immunotherapy

Using machine learning, researchers have built a tool that detects genetic mutations that trigger the immune system, helping identify which cancer patients are likely to benefit from immunotherapy.

Popular articles